New International Trial Evidence supports Lutetium Radionuclide Therapy for Prostate Cancer, available at Qscan
30/11/2021
Lutetium Radionuclide Therapy for Prostate Cancer is now supported by Randomized Multicentre Phase 3 Data. Qscan provides Lutetium Rx supported by RCT data and international trial protocols individualized to your patient.
Emerging current Rx indications:
- Upfront Lu Rx at emergence of castrate resistance in combination with other agents prior to chemotherapy
- Node positive patients with no or minimal skeletal/visceral metastases
The Qscan process:
- Initial consultation with Dr Dalveer Singh or Dr Kevin Lee with patient and family
- Evaluation of patient eligibility in conjunction with the treatment MDT
- Individualised treatment plan based on PSMA/FDG PET Imaging
- Therapy at Qscan Radiology Clinics
- Follow-up by Dr Singh and Dr Lee in conjunction with MDT
- Continued 6 weekly Rx cycles if appropriate
Case study above: 67 yr old. Metastatic castrate resistant prostate cancer, node predominant extensive disease on PET. Clinical and PSA progression. Two cycles Lutetium Rx at Qscan. Sustained CR on both PET and PSA.
Lutetium-PSMA Rx added to standard care, prolonged imaging-based progression free survival and overall survival as compared with standard care.
Lutetium-PSMA Rx compared with cabazitaxel led to a higher PSA response and fewer grade 3 or 4 adverse events.
Lutetium therapy at Qscan is offered by Dr Dalveer Singh and Dr Kevin Lee. Dr Singh and Dr Lee provide compassionate and personalised care throughout the therapy journey in close collaboration with other specialists of the multi-disciplinary team.
Click here to find a Qscan location near you
*References:
Sartor O et al; VISION Investigators. Lutetium-177-PSMA-617 for Metastatic Castration-Resistant Prostate Cancer. N Engl J Med. 2021 Sep 16;385(12):1091-1103.
Hofman MS et al. 177Lu-PSMA-617 radionuclide treatment in patients with metastatic castration-resistant prostate cancer (LuPSMA trial): a single-centre, single-arm, phase 2 study. Lancet Oncol. 2018;19:825-833.
Violet J et al. Long-term follow-up and outcomes of retreatment in an expanded 50-patient single-center phase II prospective trial of 177Lu-PSMA-617 theranostics in metastatic castration-resistant prostate cancer. J Nucl Med 2020;61:857-865.
Hofman MS et al. Lu-PSMA-617 versus cabazitaxel in patients with metastatic castration-resistant prostate cancer (TheraP): a randomised, open-label, phase 2 trial. Lancet 2021;397:797-804.